Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Cash from Financing Activities (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Cash from Financing Activities for 15 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 80.36% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.2 million through Dec 2025, up 3677.59% year-over-year, with the annual reading at $3.2 million for FY2025, 97.5% down from the prior year.
  • Cash from Financing Activities hit $2.1 million in Q4 2025 for Vistagen Therapeutics, down from $27.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $93.7 million in Q4 2023 to a low of -$397400.0 in Q1 2023.
  • Historically, Cash from Financing Activities has averaged $9.3 million across 5 years, with a median of $1.2 million in 2024.
  • Biggest YoY gain for Cash from Financing Activities was 30922.43% in 2023; the steepest drop was 1776.79% in 2023.
  • Year by year, Cash from Financing Activities stood at $2.1 million in 2021, then crashed by 114.35% to -$304100.0 in 2022, then soared by 30922.43% to $93.7 million in 2023, then crashed by 98.75% to $1.2 million in 2024, then surged by 80.36% to $2.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for VTGN at $2.1 million in Q4 2025, $27.7 million in Q3 2025, and $1.5 million in Q2 2025.